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Introduction: The recently identified claudin-low subtype of breast cancer is enriched for cells with stem-like and
mesenchymal-like characteristics. This subtype is most often triple-negative (lacking the estrogen and progesterone
receptors (ER, PR) as well as lacking epidermal growth factor 2 (HER2) amplification) and has a poor prognosis. There
are few targeted treatment options available for patients with this highly aggressive type of cancer.
Methods: Using a high throughput inhibitor screen, we identified high expression of glioma-associated oncogene
homolog 1 (GLI1), the effector molecule of the hedgehog (Hh) pathway, as a critical determinant of cell lines that
have undergone an epithelial to mesenchymal transition (EMT).
Results: High GLI1 expression is a property of claudin-low cells and tumors and correlates with markers of EMT and
breast cancer stem cells. Knockdown of GLI1 expression in claudin-low cell lines resulted in reduced cell viability,
motility, clonogenicity, self-renewal, and reduced tumor growth of orthotopic xenografts. We observed non-canonical
activation of GLI1 in claudin-low and EMT cell lines, and identified crosstalk with the NFκB pathway.
Conclusions: This work highlights the importance of GLI1 in the maintenance of characteristics of metastatic breast
cancer stem cells. Remarkably, treatment with an inhibitor of the NFκB pathway reproducibly reduces GLI1 expression
and protein levels. We further provide direct evidence for the binding of the NFκB subunit p65 to the GLI1 promoter in
both EMT and claudin-low cell lines. Our results uncover crosstalk between NFκB and GLI1 signals and suggest that
targeting these pathways may be effective against the claudin-low breast cancer subtype.Introduction
Breast cancer is a leading cause of cancer-related death
in women. There are five major intrinsic breast cancer
subtypes each with its own molecular characteristics,
prognosis, incidence, and response to treatment [1].
Claudin-low tumors are mainly triple-negative invasive
ductal carcinomas with a high frequency of metaplastic
and medullary differentiation. There are conflicting re-
ports as to the prevalence of these tumors, ranging from* Correspondence: scolavito@uwlax.edu
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mors [3-5]. Claudin-low tumor cells are enriched for
characteristics of tumor-initiating cells and across a
differentiation spectrum are most similar to mammary
epithelial stem cells [5]. Claudin-low breast cancers are
characterized by low expression levels of cell-cell adhe-
sion molecules including E-cadherin and several of the
tight junction claudin proteins, claudin 3, 4, and 7. This
subtype is molecularly similar to cells that have under-
gone an epithelial-to-mesenchymal transition (EMT)
and overlaps with the recently characterized mesen-
chymal and mesenchymal stem-like subclassifications of
triple-negative breast cancer [6,7]. Little is known aboutl Ltd. This is an Open Access article distributed under the terms of the Creative
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type of breast cancer.
EMT cells undergo a morphological transition from
the epithelial polarized phenotype to the mesenchymal
fibroblastoid phenotype. This process is marked by loss
of cell-cell adhesion molecules, such as E-cadherin,
downregulation of epithelial differentiation markers, and
upregulation of mesenchymal markers. In cancer, it is hy-
pothesized that EMT cells gain migratory potential at the
expense of proliferative ability. EMT has therefore been
implicated in the process of metastasis. There is a close
association between the EMT core signature and the sig-
natures that define the claudin-low and metaplastic
breast cancer subtypes [7].
In vertebrates, canonical Hedgehog (Hh) pathway sig-
nal transduction occurs when one of the three ligands,
Sonic, Indian, or Desert hedgehog, binds to the receptor
Patched-1 (PTCH1) or its homolog, Patched-2. In the
off-state, PTCH1 inhibits the activity of Smoothened
(SMO). When stimulated by ligand this repression is
lifted due to internalization and degradation of PTCH1.
SMO then promotes the dissociation of the Suppressor
of fused-Gli complex through an unknown mechanism.
This allows for translocation of glioma-associated onco-
gene 1 (GLI1) and GLI family zinc finger 2 (GLI2) to the
nucleus and degradation of the repressor form of GLI
family zinc finger 3 (GLI3). In the nucleus, activated GLI
proteins stimulate the transcription of Hh target genes,
including PTCH1 and GLI1. PTCH1 is a Gli target, pro-
viding a negative feedback mechanism whereby the
pathway is regulated. GLI1 is the key final output of the
Hh pathway, and GLI1 transcription is the most reliable
marker of pathway activation [8]. The Hh pathway plays
a critical role in vertebrate development, and is respon-
sible for controlling cell fate, patterning, survival, prolif-
eration and differentiation. In the adult organism Hh is
active in the maintenance of stem cells [9]. Deregulation
of this pathway can result in cancer.
There is evidence of a role for the Hh pathway in
breast cancer. Some tumors exhibit loss of chromosomal
regions containing PTCH1 or amplification of regions
containing GLI1 [10], and Hh expression in the stroma
is important [11]. Additionally, there is evidence for loss
of PTCH1 expression due to promoter methylation in
human breast cancer, which correlated with decreased
expression in samples from human ductal carcinomas in
situ (DCIS) and in invasive ductal carcinomas [12]. Simi-
larly, SMO has been found to be ectopically expressed in
approximately 70% of DCIS samples, and 30% of inva-
sive breast cancers [13]. Despite strong evidence for Hh
pathway activation in breast cancer, overall few muta-
tions in Hh pathway components have been identified
[14]. GLI1 is amplified in glioblastoma and has been
implicated in other cancers. GLI1 expression in micecauses mammary tumors with a basal-like phenotype
[15]. Additionally, mammary stem cells are regulated
by Gli transcription factors [16], and GLI1 has been
associated with poorer outcome in ERα− tumors [17] and
overall [18,19].
The nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NFκB) pathway plays a role in inflamma-
tion, cell survival, and transformation in response to
stimuli including stress, cytokines, and microbial anti-
gens. NFκB proteins are transcription factors, and in-
appropriate regulation of this family has been implicated
in inflammatory and autoimmune diseases as well as
cancer. Subunits of NFκB include v-rel avian reticuloen-
dotheliosis viral oncogene homolog (Rel) family mem-
bers RELA/p65, RELB, and c-REL, and NFκB subfamily
members p105/p50 and p100/p52. NFκB family mem-
bers associate with nuclear factor of kappa light polypep-
tide gene enhancer in B-cells inhibitor, alpha (IκBα),
which sequesters them in the cytoplasm, and they are
generally not active unless they dimerize with Rel sub-
family members. NFκB has been implicated in the pro-
gression of breast cancer. For example, NFκB promotes
cell migration and metastasis by upregulating expression
of chemokine receptor CXCR4 [20]. CXCR4 is highly
expressed in metastases from breast cancer patients, and
is thought to play a role in homing of tumor cells to the
bone marrow.
In order to identify possible drivers of proliferation in
mesenchymal stem-like breast cancer, we conducted an
inhibitor screen of human mammary epithelial cells
(HMLE) induced to undergo an EMT. The results indi-
cate the importance of GLI1 signaling in these cells,
which further extended to a panel of claudin-low cancer
cell lines. We identified non-canonical NFκB activation
of GLI1 in these cells, indicating crosstalk between GLI1
signaling and NFκB pathways in claudin-low and EMT
breast cancer cells and suggesting a therapeutic route
for claudin-low breast cancer.
Methods
The experiments described did not include human sub-
jects. All tumor data analyzed came from published ex-
pression datasets, which sought and obtained ethical
approval and used Institutional Review Board approved
protocols [5]. All animal studies were conducted in ac-
cordance with international, national, and university ap-
proved laws and policies. The animal studies received
ethical approval from Yale University’s Institutional Animal
Care and Use Committee.
Cell culture
HMLE-EMT and control cell lines were a gift of Robert A.
Weinberg (Massachusetts Institute of Technology,
Cambridge, MA) and were propagated as previously
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Taylor-Papadimitriou [23]. Claudin-low cell lines, BT549,
HS578T, MDA.MB.157, MDA.MB.231, and MDA.MB.436
as well as MCF10a, were obtained from American Type
Culture Collection (ATCC) and propagated according to
instructions. All experiments were done on low-passage
cells.
High-throughput screen and dose-response curves
A total of 750 HMLE-shEcad cells per well were plated
in 384-well plates in 20 μl of growth media and
allowed to adhere overnight. The following day 10 nl
of compounds from stock plates were added to each well
(Table S1 in Additional file 1). The stock plates contained
each agent at 16 concentrations from 10 mM to 0.3 nM.
Seventy-two hours after drug addition, viability was
assayed using CellTiter-Glo reagent (Promega, Madison,
WI, USA). The protocol for the screen has been previ-
ously described by our laboratory [24].
For generating dose-response curves manually, 1,000
cells/well in 100 μl of media were plated in 96-well
plates. Drug treatment and viability analysis was con-
ducted as described above. Dose-response curves were
generated using Graphpad Prism with Michaelis-Menten
kinetics (Graphpad Software, Inc., San Diego, CA, USA).
RNA isolation and real-time PCR
RNA was isolated using the RNeasy Plus kit (Qiagen,
Germantown, MD, USA) and cDNA synthesized using
the iScript kit (Bio-Rad Laboratories, Hercules, CA,
USA) according to manufacturers’ protocols. Real-time
PCR was performed on a Bio-Rad iCycler after combin-
ing the cDNAs with TaqMan universal PCR master mix
and premixed FAM-labeled TaqMan probes (Applied
Biosystems, Foster City, CA, USA). Abundance of mRNAs
relative to GAPDH controls was calculated using the
2-ΔΔCt method.
Cell lysis and immunoblotting
Lysates were prepared from subconfluent cells using
NP40 lysis buffer (1.0% NP40, 150 mM NaCl, 50 mM
Tris-HCl pH 7.4, 5 mM EDTA, 10% glycerol) with pho-
phatase and protease inhibitors added. Lysates were
transferred to polyvinylidine fluoride membranes and
blocked in 5% nonfat milk in phosphate-buffered saline
(PBS) with 0.1% Tween-20 (PBST). The primary anti-
bodies used recognize GLI1, pEGFR, and ERBB2 (Cell
Signaling Technology, Danvers, MA, USA) or epidermal
growth factor receptor (EGFR), glyceraldehyde phosphate
dehydrogenase (GAPDH) (Santa Cruz Technology, Santa
Cruz, CA, USA). Membranes were washed with PBST and
incubated with horseradish peroxidase-conjugated second-
ary antibodies. Gli1 blots were blocked in 5% bovine serum
albumin (BSA).Gene expression analysis of tumors
Analysis of published expression data (Gene Expression
Omnibus: GSE18229) from 337 mammary tumors and
primary tissue was conducted using the UNC337 dataset
[5]. The expression level of GLI1 across the predefined
subtypes was determined for each dataset following me-
dian centering using GEO2R. Results were analyzed by
one-way analysis of variance (ANOVA).
shRNA and retroviral infection
The following short hairpin (sh)RNA) sense sequences
were cloned into the pSIREN-RetroQ (BD Biosciences,
Franklin Lakes, NJ, USA) shRNA-expressing retroviral
vector: GLI1 #1: CCCAGATGAATCACCAAATTCAA
GAGATTT [25] and #2: AAGCGTGAGCCTGAATCTG
TG [26]. RELA: GCTGTGTTCACAGACCTGGCATCCG
TCGA [27]. NFKB1: GCCAGAGTTTACATCTGA [28].
The negative control vector contains a scrambled sequence
of a luciferase-directed shRNA (BD Biosciences).
For inducible shRNA-expressing viruses targeting RELA,
the RHS4430-200223785 and RHS4430-200229897 GIPZ
clones were purchased from Thermo Fisher Scientific
(Waltham, MA, USA) and cloned in to pInducer10
via MluI and XhoI. Non-targeting sense sequence was
5′-GGATTCCAATTCAGCGGGAGCCTG-3′ [29]. Virus
was produced by co-transfection of the pInducer10 con-
structs and packaging plasmids into 293 T cells. Virus was
harvested and concentrated, and cells were infected and
selected as described above. To induce expression of the
hairpin, cells were treated with 1 μg/ml doxycycline for
three days.
shRNA-expressing retroviruses were produced by co-
transfection of the retroviral plasmids, pVSV-G and
pCL-ECO (Clontech, Mountain View, CA, USA), into
HEK 293 T cells (ATCC) using FuGene6 (Roche, Basel,
Switzerland). Retrovirus was harvested in OptiMEM
(Invitrogen) for five days, pooled, and concentrated with
Centricon plus-20 columns (Millipore, Billerica, CA USA).
Cells were infected at a multiplicity of infection of approxi-
mately five and selected in medium containing 0.6 μg/ml
puromycin for at least three days before use.
Proliferation assay
Cells infected with retrovirus were plated in 6-well
dishes in medium containing 0.6 μg/ml puromycin.
Every 24 hours, one well was trypsinized and counted
using a Countess tissue culture counter (Invitrogen,
Carlsbad, CA, USA).
Migration assay
Retrovirally infected cells were selected for three days
in medium containing 0.6 μg/ml puromycin, and plated
in an 8.0 μm pore cell culture insert (BD Biosciences) in
medium containing 1% fetal bovine serum (FBS), above
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scraped from the inside of the insert, and the insert was
stained using Diff-Quik (Siemens, Erlangen, Germany).
Cells in at least five fields of view were counted for each
insert.
Colony formation assay
Retrovirally infected cells were selected for three days
in medium containing 0.6 μg/ml puromycin and plated
at limiting dilutions in growth medium containing
0.6 μg/ml puromycin. Colonies were grown for 12 to
14 days, stained with Diff-Quik (Siemens), and counted
under light microscopy.
Sphere formation assay
A total of 40,000 cells were plated on 60 mm ultra-
low attachment plates (Corning, Inc., Corning, NY,
USA) in 4 mL of mammosphere growth medium
(mammary epithelial basal medium (Lonza Group Ltd,
Basel, Switzerland) with B27 supplement (Invitrogen),
EGF (20 ng/mL), bFGF (20 ng/mL), heparin (7 μg/ml),
and penicillin/streptomycin with 0.5% methylcellu-
lose, adapted from [30]). Medium was replaced every
48 hours for 12 days, and spheres were counted under
light microscopy.
For secondary sphere formation, primary sphere cul-
tures were filtered using a 70 μm nylon cell strainer, to
retain spheres of larger than 70 μm in diameter. Spheres
were trypsinized until they dissociated to single cells.
Cells were counted, and 20,000 cells were plated on the
ultra-low attachment plates, following the same condi-
tions as listed above for primary sphere formation.
Flow cytometry
Cells were plated at 5 × 104 cells/well in 6-well format
and allowed to adhere overnight. The following day, cells
were treated with 0.02 μM JK184 or 0.0002% DMSO
vehicle control. After four days, floating cells were com-
bined with adherent cells harvested by trypsinization
and analyzed by flow cytometry using the BD Biosci-
ences Pharmingen (San Diego, CA, USA) FITC Annexin
V Apoptosis Detection Kit I. Samples were analyzed with
the BD FACScaliburS flow cytometer with recording of
15,000 events per sample. Each line was treated inde-
pendently and analyzed in three biological replicates.
Gates were based on negative control signals, and plots
generated using FlowJo 8.8.2 (Tree Star, Inc., San Carlos,
CA, USA).
Orthotopic xenograft studies
MDA.MB.436 cells with shGLI1 or control shRNA
were trypsinized, washed twice in sterile 1 × PBS, and
resuspended 1:1 in growth factor reduced matrigel
(BD Biosciences). Cells were maintained on ice untilinjection. 2 × 106 control (NT) cells were injected into the
right fourth mammary fat pad of five-week-old female
NOD/SCID mice (NOD.CB17-Prkdcscid/J, The Jackson
Laboratory, Bar Habor, ME, USA). A contralateral injection
was conducted, with 2 × 106 shGLI1 cells injected into the
left fourth mammary fat pad of each mouse.
Tumor growth was monitored using digital calipers,
and tumor volume was calculated using the formula:
W2 × L × 0.5, where L is the longer dimension and W
the shorter. After seven weeks, animals were sacrificed
and the tumors excised and weighed.
Immunofluorescence
Cells were plated on glass chamber slides. The next day
cells were washed twice with PBS and fixed in 2% para-
formaldehyde with 0.1% Triton-X-100 in PBS for 15′ at
room temperature (RT). Cells were washed twice in
PBS, and quenched in 100 mM glycine in PBS for 5′ at
RT. The slides were washed in PBS and permeabilized in
0.1% Triton-X-100 in PBS for 15′ at RT with humidifica-
tion, followed by blocking in 5% BSA in PBST for 30′ at
37°C with humidification. Primary antibodies against
p50 and p65 (Cell Signaling Technology) were diluted
1:250 with PBST and incubated overnight at 4°C with
humidity. Slides were washed thrice with PBST, and in-
cubated with Alexa Fluor 594-conjugated secondary
antibody (Invitrogen) diluted 1:1000 in PBST for 1 h at
RT. Slides were washed thrice with PBST and PBS, and
mounted with Prolong Gold (Invitrogen).
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed according to published protocols
with minor modifications [31]. Briefly, cells grown to
80% confluency were fixed in 1% formaldehyde for 10′
at RT, followed by 0.125 M glycine quench. Plates were
rinsed twice with PBS, and adherent cells were scraped
in ice-cold PBS and collected by centrifugation. Cells
were lysed on ice in buffer with protease inhibitors
(5 mM PIPES pH 8, 85 mM KCl, 1% v/v igepal) using a
dounce homogenizer. After centrifugation, the nuclei
pellet was lysed on ice in buffer containing protease in-
hibitors (50 mM Tris-HCl pH 8, 10 mM EDTA, 1% w/v
SDS). The chromatin was sonicated on ice for 15′
with a 30″-on/30″-off cycle using a Biorupter UCD-
200 (Diagenode Inc., Denville, NJ, USA) set to high. The
chromatin was cleared by centrifugation, and for each
ChIP from 107 cells was diluted to 1 mL with buffer con-
taining protease inhibitors (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1% v/v igepal, 0.25% w/v deoxycholic acid,
1 mM EDTA, pH 8). Antibody was added (Histone H3,
p65, and IgG from Cell Signaling Technology) and incu-
bated at 4°C overnight on a rotating platform.
A total of 30 μl of magnetic protein G beads (Cell
Signaling Technology) were added to each ChIP, and
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were washed twice with dilution buffer, three times with
100 mM Tris-HCl pH 9, 500 mM LiCl, 1% v/v igepal,
1% w/v doxycholic acid, and once with 100 mM Tris-
HCl pH 9, 500 mM LiCl, 150 mM NaCl, 1% v/v igepal,
1% w/v doxycholic acid. Antibody/chromatin complexes
were eluted in 100 μl buffer (50 mM NaHCO3, 1% w/v
SDS) for 1 h at RT. The samples were adjusted to 0.54 M
NaCl, and incubated at 67°C overnight to reverse the
crosslinks.
Samples were treated with RNaseA, and purified using
a PCR cleanup kit (Qiagen). Real-time PCR was conducted
using iQ SYBR Green Supermix (Bio-Rad Laboratories)
on a CFX96 Real-Time System thermal cycler (Bio-Rad
Laboratories) with 15 μl reactions, in triplicate. The fol-













EMT cells are more sensitive to GLI1 inhibitor
HMLE-shEcad cells are HMLE with E-cadherin knock-
down [21], which results in EMT associated with
mesenchymal-like and stem-like characteristics [7,22].
In order to identify possible drivers of proliferation, these
cells were assayed for growth inhibition by a panel of 150
compounds at 16 doses each. Overall, the HMLE-shEcad
cells were more resistant to this panel of inhibitors than
were the control HMLE-shGFP cells (Figure 1A and
Table S1 in Additional file 1). In every case where the re-
sponse between the two cell lines differed by an IC50
value of more than 0.01 μM for standard of care therapies
for triple-negative breast cancer, the HMLE-shEcad cell
lines had a poorer response (higher IC50 value) than the
control cell line.
Interestingly, epidermal growth factor receptor (EGFR)
inhibitors erlotinib and gefitinib profoundly inhibited
the proliferation of the control cell lines, while the EMT
cell lines were resistant to this treatment, with neither
EGFR inhibitor approaching 50% growth inhibition at
concentrations up to 10 μM (Figure S1A-C in Additional
file 1). In follow-up studies we observed that despite
having an intact EGFR pathway, HMLE-shEcad cells lack
high levels of baseline phosphorylated EGFR, and have
lower levels of EGFR overall, possibly rendering themimmune to EGFR-inhibitor treatment, and suggesting
that the cells do not rely on EGFR signaling for survival.
ERBB2 levels do not differ between control or EMT cells
(Figure S1D-F in Additional file 1). The lack of response
to EGFR inhibition is in concordance with the recent
finding that activation of the EMT program effects a
shift from EGFR to platelet-derived growth factor recep-
tor (PDGFR) signaling [32].
While the HMLE-shEcad cells were more resistant
overall to the panel of inhibitors, there were a few com-
pounds that selectively inhibited the growth of the EMT
cells compared to controls. One such agent was the GLI1
inhibitor JK184 [33], which was more active against
HMLE-shEcad cells than controls. The IC50 value for
JK184 was 3.5-fold lower for the HMLE-shEcad cells com-
pared to the control HMLE-shGFP cell line (0.004 μM
compared to 0.014 μM, Figure 1B). The dose-response
curve for the HMLE-shEcad cells was shifted to lower
doses compared to the HMLE-shGFP curve, indicating a
concentration window between 0.001 to 0.1 μM in which
JK184 is more effective on the EMT cells. This select-
ive sensitivity to the GLI1 inhibitor was confirmed in
another EMT cell line, HMLE-Snail [22], which was
similarly more sensitive to JK184 compared to HMLE-
pBP control cells (Figure 1C). Immunoblot and real-
time PCR analysis indicated that both EMT cell lines
have higher protein and transcript levels of GLI1 than
controls, as well as elevated levels of GLI2, while the
extent of GLI3 expression was consistent across the
cell lines (Figures 1D and 2B).
Treatment of both EMT cell lines with the IC25 and
IC50 doses of JK184 yielded a dose-dependent decrease
in GLI1 protein and transcript levels (Figure 1D-E).
GLI1 positively regulates its own transcription [34], so it
is likely that the JK184-dependent decrease in GLI1 tran-
script and protein levels arises from decreased activity of
the JK184 target GLI1. GLI2 and GLI3 are not direct tar-
gets of GLI1, and neither GLI2 nor GLI3 transcript levels
were affected in JK184-treated HMLE cells (Figure S2A-B
in Additional file 1).
Claudin-low cell lines express elevated levels of Gli
proteins and are more sensitive to the GLI1 inhibitor
We next determined if Gli expression is associated with
a particular breast cancer subtype. Using a previously
published dataset, cell lines were clustered based on
CD24, CD44, E-cadherin (CDH1), and CLDN3, 4, and 7
expression status [35]. This reveals a subgroup of basal
B cell lines identified as claudin-low [5,36]. Claudin-low
tumors express decreased levels of CDH1, are enriched
for EMT markers, and are CD24 low/CD44 high, which
are features of self-renewing breast cancer stem cells [5].
Within the basal subtype, the claudin-low cells gener-
ally express higher levels of GLI1, GLI2, and GLI3
Figure 1 JK184 is more effective at inhibiting EMT cell proliferation. (A) Clustering of Spearman ranked data of inhibition concentration (IC)
values for the inhibitor screen. Rank values are as follows for μM concentrations: 1: no IC values are between 0 and 10; 2: IC10 between 0 and 10,
and IC25 not between 0 and 10, and IC50 not between 0 and 10; 3: IC25 between 0 and 10, and IC50 not between 0 and 10; 4: IC50 between 0.1 and
10; 5: IC50 between 0.01 and 0.1; 6: IC50 between 0.001 and 0.01; 7: IC50 < 0.001. Asterisks mark the agents mentioned in the text. (B) Dose-response
curve for JK184 treatment of HMLE-shEcad cells (blue) and HMLE-shGFP cells (green). Error bars indicate coefficient of variance between triplicate
treatment. (C) Dose-response curve for JK184 treatment of HMLE-shEcad cells (blue), HMLE-shGFP cells (green), HMLE-Snail cells (purple), and
HMLE-pBP cells (gray). Treatment was conducted in 96-well plates. (D) Immunoblot showing response of GLI1 expression in HMLE cells with JK184
drug treatment. Doses were 0, 0.002, and 0.004 μM JK184 for 72 h. GAPDH serves as a loading control. GLI1 quantification levels were normalized to
HMLE-shEcad untreated levels, and appear below the lane numbers in the figure. (E) Real-time PCR data showing relative GLI1 mRNA transcript
levels from cells treated as in D). Error bars represent standard error between two independent experiments. * = P ≤0.05, t test. ** = P ≤0.005, t test.
GAPDH, glyceraldehyde phosphate dehydrogenase; GLI1, glioma-associated oncogene 1; HMLE, human mammary epithelial cells, transformed with
large T and small t antigens.
Colavito et al. Breast Cancer Research 2014, 16:444 Page 6 of 18
http://breast-cancer-research.com/content/16/5/444(Figure 2A). We confirmed this expression data in several
claudin-low cell lines, and found that similarly to the
EMT cell lines, claudin-low cells express higher tran-
script levels of the Gli family of transcription factors thando MCF10a cells, an immortalized but non-tumorigenic
mammary cell line (Figure 2B). Additionally, claudin-low
cell lines have higher protein levels of GLI1 than do
MCF10a cells (Figure 2C).
Figure 2 (See legend on next page.)
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Figure 2 Claudin-low cell lines express higher transcript and protein levels of GLI1. (A) Expression of CD44, CD24, CDH1, GLI, and CLDN3, 4,
and 7, transcripts across a panel of breast cancer cell lines [34]. Multiple probes for each gene were extracted from microarray data and their
expression values were Z transformed and plotted as a heat map. BaA = basal A, BaB = basal B, Lu = luminal. Asterisks denote cell lines originally
identified as claudin-low [5]. Yellow box surrounds the expression of Gli family members in claudin-low cell lines. (B) Graph of relative Gli family
expression levels in claudin-low (I) and EMT (II) cell lines, relative to controls. Error bars represent standard error, and n.s. indicates that no signal
was achieved under the parameters used. (C) Immunoblot of GLI1 levels in the indicated claudin-low cell lines. GAPDH serves as a loading
control. (D) Plot of GLI1 expression data from UNC337 mammary tumor and tissue dataset, based on subtype. 99% confidence interval is
shown, with outliers plotted as single data points. Significance was calculated using one-way ANOVA using multiple comparisons, and all
significant comparisons between the claudin low data set and others are indicated. ** = P ≤0.005. ANOVA, analysis of variance; EMT,
epithelial-to-mesenchymal transition; GAPDH, glyceraldehyde phosphate dehydrogenase; GLI1, glioma-associated oncogene 1.
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observed in claudin-low cell lines, we determined if
claudin-low tumors display similarly elevated GLI1
levels. An analysis of a published dataset of over 330
tumors, including 37 claudin-low tumors, revealed el-
evated GLI1 expression levels in claudin-low tumors
compared to basal tumors (P = 0.001, Figure 2D). Some
luminal A tumors express GLI1, which mirrors the ex-
pression data for the cell lines (Figure 2A).
Since claudin-low cell lines and tumors preferentially
express GLI1 transcripts, and claudin-low cells are
transcriptionally similar to the JK184-sensitive EMT
cells, we determined the dose-sensitivity of claudin-
low cell lines to JK184. Overall, claudin-low cell lines
are more sensitive to JK184 treatment than are
MCF10a, MTSV1-7, or HMLE-shGFP and HMLE-pBP
cells, and JK184 induced a dose-dependent decrease
in GLI1 transcript and protein levels in these cells
(Figure 3A-C). GLI2 and GLI3 levels were not signifi-
cantly altered with JK184 treatment (Figure S2C-D in
Additional file 1). Taken together, these data establish
similar patterns of GLI1 signaling and GLI1 inhibitor
sensitivity in EMT and claudin-low cell lines, provid-
ing further evidence for the similarity of EMT and
claudin-low cells.
GLI1 inhibitor treatment results in increased apoptosis
Since JK184 treatment reduced cell accumulation, we
identified whether there is an elevated rate of apoptosis
in JK184-treated cells. Treatment with the IC50 dose
of JK184 enhanced the proportion of HMLE-shEcad
cells that stained with Annexin-V, but were negative
for propidium iodide (PI) (P <0.0001, t test; Figure 3D).
This staining pattern is consistent with early-apoptotic
cells, while PI-positive or dual-stained cells indicate
apoptosis and/or necrosis. JK184-treated cells were
sparser and less well spread than vehicle-treated coun-
terparts (Figure 3D). JK184 treatment did not signifi-
cantly affect the staining of HMLE-shGFP cells or their
morphology (Figure 3D). Over four days of treatment
there was increased cell death of the BT549 cells, as in-
creased Annexin-V and PI staining were observed intreated cells, and these cells appeared rounded up com-
pared to vehicle-treated counterparts (P = 0.001, t test;
Figure 3D).
Knockdown of GLI1 decreases proliferation of claudin-low
cell lines
Given the markedly elevated GLI1 levels observed in the
claudin-low subtype, we wanted to determine the bio-
logical importance of GLI1 in claudin-low cell lines. We
investigated the effects of GLI1 knockdown on aggres-
sive characteristics of claudin-low tumor cells, including
proliferation, migration, and anoikis. GLI1 has been im-
plicated in several of these processes in transformed cells
[37] and in some breast cancer cell lines [38]. Since
there did not always appear to be a direct correlation be-
tween expression levels of GLI1 and sensitivity to JK184
treatment, and to avoid possible off-target effects of
JK184, we utilized a specific genetic approach to reduce
GLI1 expression. Two different shRNA viruses both
induced stable, specific knockdown of GLI1 protein
(Figure 4A) and transcript levels (Figure 4B). Neither
GLI2 nor GLI3 transcript levels were affected by
GLI1 knockdown (Figure S2E-F in Additional file 1).
Knockdown of GLI1 in MDA.MB.157 cells resulted in
cells that appeared rounder and less elongated compared
to cells with control knockdown, which maintained the
long spindle shape characteristic of mesenchymal cells
(Figure 4C). MDA.MB.157 cells have an extended doub-
ling time of greater than 60 hours, so we therefore evalu-
ated the biological effects of GLI1 knockdown in two
other claudin-low cell lines with high GLI1 expression,
BT549 and MDA.MB.436 cells. Knockdown of GLI1
greatly reduced the growth rates of these cell lines
compared to cells expressing the non-targeting shRNA
(Figure 4D-E). Proliferation of MCF10a cells, which do
not express endogenous GLI1, was not significantly af-
fected by infection with the shGLI1 retrovirus (Figure S3F
in Additional file 1). The proliferation of the immortalized
human mammary epithelial cell line MTSV1-7 was signifi-
cantly, though slightly, impaired following GLI1 knock-
down. These cells do express some GLI1 (Figure S3A-C, F
in Additional file 1).
Figure 3 JK184 inhibits growth of claudin-low cell lines. (A) Real-time RT-PCR analysis of Gli1 RNA expression in JK184-treated claudin-low cell lines.
Doses were 0, 0.002, and 0.004 μM JK184 for 72 h. Values were normalized to DMSO vehicle control, error bars are the standard error between two
independent experiments. * = P ≤0.05, t test. ** = P ≤0.005, t test. (B) Western blot showing protein expression levels in claudin-low cells treated as
in A). Lanes 19 to 21 are from a separate gel. (C) Dose-response curve for 72 h JK184 treatment of claudin-low and MCF10a, HMLE-shGFP, HMLE-pBP, and
MTSV1-7 cell lines. (D) Flow cytometric analyses of cells treated with JK184 (0.02 μM) for four days followed by staining with Annexin-V and propidium
iodide (PI). Images representative of three independent experiments. (E) Light microscopy images of cells treated as in A). Scale bar indicates 100 μm.
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anchorage-independent growth
GLI1 knockdown significantly reduced the transwell mi-
gration of BT549 and MDA.MB.436 cells in response toan FBS gradient with both GLI1 knockdown constructs
used (Figure 5A). The low FBS in the top chamber of
the transwell (1%) and the relatively short assay time
(12 h) minimized the impact of reduced proliferation
Figure 4 Knockdown of GLI1 decreases proliferation of claudin-low cell lines. (A) Western blot of cells infected with retrovirus expressing
either non-targeting shRNA (NT), or shRNA targeted against GLI1 (#1, #2). Cells were infected, and selected for three days prior to blotting. GAPDH
serves as a loading control. Quantification is relative to NT for each cell line. Blot is representative of three independent experiments. (B) Plot of
GLI1 transcript levels in response to the shRNAs and treatment described in A). Error bars represent the standard error between three independent
experiments. (C) Light microscopy images of MDA.MB.157 cells infected with either non-targeting (NT) or GLI1 -directed shRNA. Scale bars indicate
100 μm. (D, E) Plot detailing the proliferation of MDA.MB.436 cells (D) or BT549 cells (E) infected with the indicated retroviruses and grown in selection
media. GAPDH, glyceraldehyde phosphate dehydrogenase; GLI1, glioma-associated oncogene 1; sh, short hairpin.
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affected (Figure S3E in Additional file 1).
In clonogenicity assays, knockdown of GLI1 reduced
colony formation of BT549 and MDA.MB.436 cells
(Figure 5B), whereas MCF10a cells were largely unaffected
(Figure S3D in Additional file 1). Mammospheres are de-
rived from mammary cells grown under non-adherent
conditions. They are enriched in early progenitor/stem
cells and are able to differentiate along all three mammary
epithelial lineages [30]. The sphere-initiating subset of
mammary cells have cancer stem cell-like characteris-
tics, including the ability to self-renew and to differ-
entiate into mature mammary cells that lack stem cell
features [16,30]. We did not observe any significant
sphere formation resulting from either the control
HMLE-shGFP or HMLE-pBP cell lines, as has been
previously reported [22]. We also did not achieve sig-
nificant levels of spheres resulting from BT549 cells,
despite their tumorigenicity [39]. Therefore, we first inves-
tigated the effects of GLI1 knockdown on the sphere-
forming ability of MDA.MB.436 cells. GLI1 knockdown
reduced primary and secondary sphere formation by
MDA.MB.436 cells (Figure 5C). Secondary sphere forma-
tion is a measure of the self-renewal capacity of thesphere-forming cells. The ability of the cells to form sec-
ondary spheres was enhanced compared to primary sphere
forming ability, producing on average 454 secondary
spheres from 20,000 plated cells (0.055%), compared to
the average primary sphere forming ability of 254 spheres
from 40,000 plated cells (0.006%). These data, combined
with the higher GLI1 transcript and protein levels we
observed in spheres derived from EMT and/or claudin-
low cells compared to control adherent cells (Figure 5D)
indicates that GLI1 is important for formation of spheres.
Elevated GLI1 levels were seen in primary mammo-
spheres formed from normal and tumorigenic breast tis-
sue from a published dataset (Figure 2D). Higher levels
of GLI1 transcripts in mammospheres compared to dif-
ferentiated mammary cells has been reported [16,40], but
we observed that GLI1 levels in mammospheres are even
higher than those in EMT cells grown under adherent
conditions.
We also wanted to investigate the effects of GLI1
knockdown in a basal cell line, HCC1806, which expresses
elevated levels of GLI1 (Figure S3A-C in Additional
file 1). Significantly fewer spheres resulted from cells
in which GLI1 expression was reduced compared to
controls (Figure S3G in Additional file 1). Additionally,
Figure 5 (See legend on next page.)
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Figure 5 Decrease in GLI1 expression inhibits cell migration and anchorage-independent growth. (A) Panel I: Cartoon depicting
experimental setup. Cells (yellow) were plated in the top of a Boyden chamber in 1% FBS above a lower-chamber of media containing 10% FBS.
After 16 hours the number of cells that have migrated to the bottom side of the filter were stained and counted. II: Light microscopy images of
the bottom side of the migration filter after staining. BT549 cells were infected with the indicated retroviruses and selected prior to experimentation.
Scale bar indicates 100 μm. III: Migration of BT549 and MDA.MB.436 cells infected with the indicated retroviruses and assayed as described in I.
(B) Clonogenic colony formation assay in BT549 (I) and MDA.MB.436 (II) cells. (C) Panel I: Representative 12 day spheres formed in MDA.MB.436
cells infected with the indicated retroviruses. Scale bar indicates 100 μm. II: Relative sphere formation by MDA.MB.436 cells. (D) Panel I: GLI1
mRNA expression obtained from real-time RT-PCR analysis of mRNA from adherent cells incubated in mammosphere medium (white bars) or
sphere cells grown under non-adherent conditions (gray bars). II: Western blot detailing GLI1 levels in HMLE-shEcad or HMLE-Snail adherent and
sphere cells. For all: * = P ≤0.05, t test. ** = P ≤0.005, t test. (E) (I) Plot of tumor volume over time arising from orthotopic injection of MDA.
MB.436 cells infected with either non-targeting (NT) or GLI1 knockdown constructs. n = six animals. (II) Final averaged tumor weights at seven
weeks post-injection for n = six animals. (III) Final averaged tumor weights from an independent biological replicate of the orthotopic xenograft
study, conducted on four animals. FBS, fetal bovine serum; GLI1, glioma-associated oncogene 1.
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the EMT cell lines, there was significantly more GLI1
expression from HCC1806 cells grown as spheres
compared to those grown under adherent conditions
(Figure S3H in Additional file 1). This is further evidence
that GLI1 is activated and functionally important in
sphere-initiating and/or early progenitor cells across a
spectrum of cell lines.
GLI1 expression is important for tumor formation in vivo
Having shown that GLI1 is essential for the aggressive
and stem-like characteristics of claudin-low cell lines
in vitro, so we next examined the effects of GLI1 knock-
down in vivo. While previous studies have highlighted
the ability of ectopic GLI1 expression to form tumors
in vivo [15,40], we wanted to investigate the effects
of GLI1 knockdown on the tumor-forming abilities of
claudin-low MDA.MB.436 cells as orthotopic xenografts.
While all shGLI1 expressing cells eventually formed tu-
mors, GLI1 knockdown tumors were smaller on average
than tumors resulting from contralateral control knock-
downs (Figure 5E, panel I and II). Similar results were
seen for an independent biological replicate (Figure 5E,
panel III, and Figure S4 in Additional file 1). These data
are consistent with reports from other groups, in which
knockdown of GLI1 delayed onset of tumor formation
from injection of claudin-low SUM1315 cells [40], and
reduced the incidence of metastasis to the lung by
claudin-low MDA.MB.231 cells [41].
The NFκB pathway contributes to elevated GLI1 levels in
claudin-low and EMT cells
Whereas JK184 reduced GLI1 levels, cyclopamine, which
inhibits the Hh pathway through SMO, did not affect
proliferation or GLI1 levels in EMT cells (Figure 6A-C).
Additionally, two other SMO inhibitors in our screen
had no effect on accumulation of EMT cells (Figure 6A).
The ineffectiveness of cyclopamine on GLI1 expression
is consistent with published results for breast cancer
cell lines including SUM149, T47D, MCF7, and MDA.MB.231 [38,40,42]. Taken together, these data indicate
that the elevated GLI1 levels in EMT and claudin-low
cell lines are not caused by classical activation of the
pathway through SHH-PTCH1-SMO. Non-canonical ac-
tivation of the Hh pathway can occur with activation of
the Gli family, mainly GLI1, by MAPK/ERK [43], AKT
[44], KRAS [45], mTOR/S6K1 [46], and more recently
NRP2 [40]. The mechanisms of SMO-independent up-
regulation of GLI1 are poorly understood.
To determine which upstream pathways are respon-
sible for elevated GLI1 in claudin-low and EMT cells, we
screened several candidate molecules for reduction of
GLI1 expression (Figure S5A-B in Additional file 1).
Triptolide, an NFκB inhibitor [47-49] reduced GLI1
transcript and protein levels in both HMLE-shEcad and
BT549 cell lines (Figure 6D-E). The activity of triptolide
as an NFκB inhibitor was confirmed by means of a re-
porter assay (Figure S5C in Additional file 1).
Since we observed these effects without stimulation or
activation of the NFκB pathway, we hypothesized that
NFκB is basally activated in our cells. Normally, NFκB
subunits are sequestered in the cytoplasm due to inhibi-
tory interactions with IκB. However, we observed that
both the p65 and p50 subunits of NFκB present in the
nucleus of EMT cells, while they are restricted to the
cytoplasm of the HMLE control cell lines (Figure 7A).
p65 and p50 show a similar localization pattern for
claudin-low versus MCF10a cells (Figure S6 in Additional
file 1). These data suggest that NFκB is basally present in
the nucleus of EMT and claudin-low cells, and active even
without stimulation by a proinflammatory agent, in agree-
ment with some earlier reports describing constitutive
NFκB activity in basal cell lines [50-52].
NFκB binds to the GLI1 promoter in EMT and
claudin-low cells
The effects of triptolide on the expression levels of GLI1
suggest that NFκB could act as a transcription factor
to regulate GLI1 expression. We searched the gen-
omic region surrounding the transcription start site of
Figure 6 EMT and claudin-low cells are insensitive to Hedgehog (Hh) pathway inhibitors. (A) Inhibition concentration (IC)50 values obtained
with other Hh pathway antagonists from the 384-well screen. NF indicates not determined, either because no curve fit could be obtained, or the IC50
was outside the experimental concentrations tested. (B) GLI1 transcript levels in HMLE-shEcad and HMLE-shGFP cells treated with cyclopamine
(0, 5, or 10 μM for 72 hours). (C) Immunoblot of GLI1 in HMLE cells treated with cyclopamine as in B). (D) Gli1 transcript levels after 16 h treatment
with 1 μM JK184 or triptolide. Error bars indicate the standard error of two independent experiments. * = P <0.05, t test. ** = P <0.005, t test. (E) Anti-GLI1
immunoblot following treatment described in A). Lanes 1 to 3 are from a separate gel. Quantification is normalized to no treatment condition. EMT,
epithelial-to-mesenchymal transition; GLI1, glioma-associated oncogene 1; HMLE, human mammary epithelial cells, transformed with large T and small
t antigens.
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DECipherment of DNA Elements (DECODE) system
which searches for predicted binding sites of transcrip-
tion factors using data from the ENCODE project con-
sortium and the UCSC Genome Browser. Six potential
κB binding sites were identified that matched the con-
sensus κB binding sequence (Figure 7B). In order to
determine if NFκB binds to the GLI1 promoter we
conducted ChIP experiments using primer sets de-
signed to amplify each predicted binding site. Binding
of the p65 subunit of NFκB to the first predicted κB
binding site (chr12: 57851125–57851134) was enriched
over the other binding sites in unstimulated HMLE-
shEcad cells (Figure 7C). The binding of histone H3 to
the six potential κB binding sites as well as to GAPDH
serves as a positive control for the ChIP experiment
(Figure 7C).We also observed enrichment of p65 subunit binding
to Site 1 in HMLE-Snail, BT549, and MDA.MB.436 cells
(Figure S6B in Additional file 1). We did not detect en-
hanced binding of p65 subunits to Site 1 in the GLI1
promoter of HMLE-shGFP or HMLE-pBP cell lines,
despite observing enriched binding of histone H3 with
Site 1, which serves as a positive control for the ChIP
experiment (Figure S7A in Additional file 1). Overall the
ChIP data suggest that there is crosstalk between NFκB
and GLI1 signaling in EMT and claudin-low cell lines.
Since the NFκB inhibitor triptolide decreased the
expression level of GLI1, we determined the impact of
triptolide treatment on binding of p65 to the GLI1 pro-
moter. 1 μM triptolide treatment for six hours caused a
70% reduction in binding of p65 to Site 1 in the GLI1 pro-
moter of HMLE-shEcad cells compared to control vehicle
treatment (Figure 7D). This supports the conclusion that
Figure 7 Crosstalk between NFκB and GLI1 signaling pathways. (A) Immunofluorescence images showing localization of NFκB p50 (Panel I)
or p65 (Panel II) subunits in HMLE-shEcad (top row) or HMLE-shGFP (lower row) cells. Scale bar indicates 50 μm. (B) Map of putative NFκB binding
sites surrounding the GLI1 promoter. Red arrow marks transcription start site. Green lines indicate sequences matching the consensus κB binding
site; putative sites are numbered 1 to 6. Blue arrows indicate primer sets used for ChIP. (C) ChIP of HMLE-shEcad cells with indicated antibodies. Error
bars indicate standard error among three independent experiments. (D) NFκB p65 ChIP to the GLI1 promoter (site 1) following six-hour
treatment with 1 μM triptolide. Graph was normalized to binding with vehicle control (DMSO). Error bar indicates standard error among
three independent experiments. (E) Real-time PCR data showing RELA, NFKB1, and GLI1 transcript levels after infection of HMLE-shEcad cells
with non-targeting (NT) or shRELA and shNFKB1 virus (shNFκB) virus. (F) Western blot of Gli1, p65, and p50 levels in HMLE-shEcad cells infected with
either non-targeting (NT) or shRELA and shNFKB1 virus (shNFκB). GAPDH serves as a loading control. For all: * = P ≤0.05, t test. ** = P ≤0.005, t test.
ChIP, chromatin immunoprecipitation; GLI1, glioma-associated oncogene 1; RELA, v-rel reticuloendotheliosis viral oncogene homolog A; NFKB1, nuclear
factor of kappa light polypeptide gene enhancer in B-cells 1; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; sh, short hairpin.
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of NFκB transcriptional complexes to the GLI1 promoter.
Knockdown of NFκB results in decreased GLI1 expression
Although triptolide has been shown to inhibit NFκB,
it is not entirely specific. In order to reinforce the con-
nection between NFκB and elevated GLI1 levels, we
determined the impact of NFκB knockdown on GLI1 ex-
pression. Combined reduction of RELA of approximately
60%, and of NFKB1 by 40% reduced GLI1 expression at
both the protein and transcript level in HMLE-shEcad
cells (Figure 7E-F) and similar results were seen with
knockdown of both NFκB subunits in MDA.MB.436
cells (Figure S7C in Additional file 1). Doxycycline-
inducible knockdown of RELA of approximately 75%
with two separate hairpins reduced GLI1 expression
(Figure S7D in Additional file 1). Hence, GLI1 is regu-
lated by NFκB in claudin-low and EMT cells.
Discussion
Currently, there are no targeted treatment options
for patients with claudin-low breast cancer, a particu-
larly aggressive type of breast cancer. We used mam-
mary carcinoma cell lines with induced EMT as
surrogates for cells with stem-like characteristics and
screened them for growth sensitivity to 150 targeted
agents. Selective sensitivity of these cells to inhibition
of GLI1 implicated GLI1 as a vulnerable target. The
transcriptional similarities of induced EMT mammary
cells to claudin-low breast cancer suggested the po-
tential importance of GLI1 for this breast cancer subset.
Reduced GLI1 expression impeded migration, clono-
genicity, primary and secondary mammosphere forma-
tion and tumor formation by claudin-low breast cancer
cells. These characteristics are associated with stem-
like, invasive, and aggressive aspects of breast cancer,
and suggest that inhibiting GLI1 may be an effective
treatment strategy for patients with claudin-low breast
cancer.
Our work reveals novel SMO-independent activation
of GLI1 by the NFκB pathway, in which the p65 subunit
of NFκB binds directly to the GLI1 promoter in EMT
and claudin-low cells (Figure 7C). We have only ob-
served binding of the p65 subunit to one κB binding site
in the GLI1 promoter, but this does not preclude binding
of NFκB subunits to the remaining putative κB binding
sites in the GLI1 promoter, perhaps following cytokine
stimulation. Knockdown of NFκB subunits resulted in
decreased GLI1 expression (Figure 7D-E), indicating
transcriptional regulation of GLI1 by NFκB. GLI1 levels
were not completely abrogated following knockdown of
NFκB subunits, indicating either that residual NFκB
activity is sufficient to sustain GLI1 expression, or that
other pathways contribute to GLI1 transcription.We also found that NFκB is activated through a non-
canonical pathway in EMT and claudin-low cells. Typic-
ally, in the absence of an inflammatory signal NFκB
dimers are sequestered in the cytoplasm by IκBα. How-
ever, we observed NFκB in the nucleus of EMT and
claudin-low cells (Figure 7A and Figure S5 in Additional
file 1) without stimulation, indicating that NFκB is
present in an activated form in the nucleus. Interest-
ingly, we observed less nuclear NFκB in claudin-low cell
lines, which express less GLI1, notably HS578T and
MDA.MB.231 cells. This association fits with our data
indicating transcriptional regulation of GLI1 by NFκB,
and speaks to the molecular heterogeneity of the
claudin-low subclass. Indeed, while claudin-low tumors
express more GLI1 than the basal, human epidermal
growth factor receptor 2 (Her2), and luminal B subtypes
overall, there still existed heterogeneity within this sub-
set (Figure 2D). Activated NFκB [53] and expression of
GLI1 [17-19] have been associated with poor prognosis
in breast cancer. It will be interesting to see if NFκB ac-
tivity and GLI1 expression are correlated in mammary
tumors. Recently, nuclear GLI1 expression was shown to
be closely correlated with nuclear expression of NFκB in
pancreatic cancer, and both were associated with shorter
overall survival and worse outcome [54]. It will be inter-
esting to determine if a similar phenomenon occurs
in breast cancer, and if patients with tumors that co-
express NFκB and GLI1 have a worse outcome.
Constitutive activation of NFκB in nuclear lysates from
breast cancer cells has been observed [55], and it will be
interesting to determine the responsible factors that con-
tribute to NFκB pathway activation in EMT and claudin-
low cells. One possibility is ERBB3, since recent work
has revealed that the ERBB3 ligand heregulin increases
mammosphere formation in breast cancer cell lines,
which was attenuated by NFκB pathway inhibition [56].
It will be interesting to explore the role of ERBB3 on
NFκB in claudin-low cells and EMT, especially given
our findings with EGFR in EMT cells (Figure S1 in
Additional file 1) and the known interactions among
ERBB family members in breast cancer [57]. Recently
Yamamoto et al. identified activated NFκB in basal and
claudin-low tumors, and a correlation between NFκB
activity and JAG1 expression, which was associated
with poor prognosis in the basal subset [52]. These re-
sults combined with our findings suggest that NFκB
could affect different downstream targets depending on
subtype, namely JAG1 in basal and GLI1 in claudin-low
tumors.
Our work supports earlier studies implicating GLI1
signaling in some breast cancer cell lines, albeit through
different mechanisms. GLI1 expression is elevated in
SUM1315 cells, and knockdown of GLI1 in MDA.MB.231
cells reduces cell growth, invasion, and metastasis [41].
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shown to decrease the migratory ability of these cells, and
to increase apoptosis [38]. We have extended these find-
ings to the claudin-low subtype as a class, and our findings
lend evidence to the potential of GLI1 as a therapeutic
target in breast cancer.
There is increasing evidence for non-canonical Hh
pathway activation in a variety of cancers [46] including
breast [38,42]. Recently, Goel et al. demonstrated a con-
tribution of Neuropilin-2 (NRP2), a vascular endothelial
growth factor (VEGF) co-receptor, to GLI1 levels in
claudin-low cell lines [40]. A non-canonical mechanism
was implicated, since SMO knockdown did not interfere
with the process. It will be of interest to determine if
NRP2 exerts its effects on GLI1 through NFκB. Al-
though the NFκB and Hh pathways are implicated in
breast cancer, and these pathways share some common
downstream targets [58], to our knowledge direct tran-
scriptional crosstalk between the two pathways in breast
cancer has not yet been reported.
Although our studies focused on GLI1, GLI2 expres-
sion is also elevated in EMT and claudin-low cells
(Figure 2A-B). While GLI1 is itself a GLI1 regulatory
target [34], in basal cell skin carcinoma cells, activa-
tion of GLI2 by GLI1 is indirect, and perhaps context
dependent [59]. There are no consensus Gli or κB
binding sites in the GLI2 promoter. Therefore, it is
likely that the regulation of GLI2 expression in these
cells occurs via a different mechanism than that de-
scribed here for GLI1. Similarly, while some GLI1 tar-
gets have been identified [37], the activity of the Gli
proteins is highly context dependent [34], and it will
be of great interest to determine the effectors through
which Gli1 mediates the biological phenotypes we ob-
served in claudin-low lines.
EMT cells and claudin-low cells are closely related to
cancer stem cells [5-7]. There is evidence for Hh signal-
ing in normal and malignant human mammary stem
cells, and upregulation of GLI1 in mammospheres [16].
We observed upregulation of GLI1 in mammospheres,
and a decrease in primary and secondary sphere forma-
tion after GLI1 knockdown (Figure 5C), strongly sug-
gesting a role for GLI1 in maintenance of breast cancer
stem cells/progenitor cells. Elevated levels of GLI1
transcripts were also seen in a published dataset of
mammospheres grown from primary patient material
(Figure 2D). We have shown here evidence of cross-
talk between the GLI1 signaling and NFκB pathways in
both EMT and claudin-low cell lines, indicating that acti-
vated GLI1, could be a mechanism that also operates in
breast cancer stem cells. Recent reports substantiating
the existence of cancer stem cells in solid tumors [60]
reinforce the potential importance of these findings for
breast cancer therapy.Conclusions
Several SMO antagonists are in clinical trials for the treat-
ment of various cancers [61]. However, our findings indi-
cate that, while bulk tumor and/or stromal cells may
respond to SMO inhibitors, the tumor-initiating stem-like
cells may not respond, possibly allowing for tumor resist-
ance and recurrence. Crosstalk between these two key in-
flammatory and developmental pathways has important
biological implications, and provides a rationale for com-
bination therapy in the treatment of patients with claudin-
low breast cancer. An increased molecular understanding
of the signaling drivers in EMT and claudin-low cells may
not only help patients with claudin-low or mesenchymal-
like cancers, but could also aid in the prevention of metas-
tasis and recurrence in breast cancer patients in general.
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